<DOC>
	<DOCNO>NCT01688401</DOCNO>
	<brief_summary>The goal pilot study determine intra-arterial ( IA ) chemotherapy safe treatment progressive diffuse intrinsic pontine glioma ( DIPG ) . IA administration chemotherapeutic agent enhances regional distribution drug , thereby increase local deliver dose minimize systemic toxicity . It also provide treatment option patient time tumor recurrence .</brief_summary>
	<brief_title>Intra-arterial Chemotherapy Treatment Progressive Diffuse Intrinsic Pontine Gliomas ( DIPG ) .</brief_title>
	<detailed_description>Delivering chemotherapeutic agent directly tumor via arterial system avoids complication adverse event associate toxicity systemic chemotherapy .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Pediatric patient age progressive DIPG . Consensus follow presentation case multidisciplinary Pediatric NeuroOncology conference , include participation neurooncology , neurosurgery , radiation oncology , interventional neuroradiology neurology . Documented hypercoagulable disorder vasculopathies INR value Grade 1 toxicity CTCAE v 4.0 criterion ( &gt; 1 1.5 x ULN ; &gt; 1 1.5 time baseline anticoagulation ) . APTT value Grade 1 toxicity CTCAE v 4.0 criterion ( &gt; ULN 1.5 x ULN ) . Platelets less 50 x 103/mm3 Absolute neutrophil count le 500/ mm3 Pregnancy Documented severe allergic reaction IV iodinate contrast , specifically bronchospasm anaphylaxis .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>diffuse intrinsic pontine glioma ( DIPG )</keyword>
	<keyword>intra-arterial chemotherapy</keyword>
	<keyword>angiography</keyword>
</DOC>